Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial.

Bardia A, Parton M, Kümmel S, Estévez LG, Huang CS, Cortés J, Ruiz-Borrego M, Telli ML, Martin-Martorell P, López R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz SA, Mayer IA, Carreon D, Cameron S, Liao S, Baselga J, Kim SB.

J Clin Oncol. 2018 Sep 20:JCO2017748392. doi: 10.1200/JCO.2017.74.8392. [Epub ahead of print]

PMID:
30235087
2.

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A.

Breast Cancer Res Treat. 2018 Sep 15. doi: 10.1007/s10549-018-4959-8. [Epub ahead of print]

PMID:
30220055
3.

Molecular dynamics of pancreatic transcription factors in bioengineered humanized insulin producing neoorgan.

Vishwakarma SK, Lakkireddy C, Bardia A, Raju N, Paspala SAB, Habeeb MA, Khan AA.

Gene. 2018 Oct 30;675:165-175. doi: 10.1016/j.gene.2018.07.006. Epub 2018 Jul 3.

PMID:
30180963
4.

Predictors of systemic therapy sequences following a CDK 4/6 inhibitor-based regimen in post-menopausal women with hormone receptor positive, HEGFR-2 negative metastatic breast cancer.

Princic N, Aizer A, Tang DH, Smith DM, Johnson W, Bardia A.

Curr Med Res Opin. 2018 Sep 20:1-8. doi: 10.1080/03007995.2018.1519500. [Epub ahead of print]

PMID:
30175631
5.

A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer.

Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S.

Cancer Discov. 2018 Aug 13. doi: 10.1158/2159-8290.CD-18-0432. [Epub ahead of print]

PMID:
30104333
6.

Protective Role of Hypothermia Against Heat Stress in Differentiated and Undifferentiated Human Neural Precursor Cells: A Differential Approach for the Treatment of Traumatic Brain Injury.

Vishwakarma SK, Bardia A, Fathima N, Chandrakala L, Rahamathulla S, Raju N, Srinivas G, Raj A, Sandhya A, Satti V, Tiwari SK, Paspala SAB, Khan AA.

Basic Clin Neurosci. 2017 Nov-Dec;8(6):453-466. doi: 10.29252/NIRP.BCN.8.6.453.

7.

Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances.

Bardia A, Hurvitz S.

Clin Cancer Res. 2018 Jun 8. doi: 10.1158/1078-0432.CCR-18-0162. [Epub ahead of print] Review.

PMID:
29884743
8.

Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS.

Lancet Oncol. 2018 Jul;19(7):904-915. doi: 10.1016/S1470-2045(18)30292-4. Epub 2018 May 24.

PMID:
29804902
9.

Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer.

Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K.

Clin J Oncol Nurs. 2018 Jun 1;22(3):E71-E77. doi: 10.1188/18.CJON.E71-E77.

PMID:
29781452
10.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

11.

A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.

Santa-Maria CA, Bardia A, Blackford AL, Snyder C, Connolly RM, Fetting JH, Hayes DF, Jeter SC, Miller RS, Nguyen A, Quinlan K, Rosner GL, Slater S, Storniolo AM, Wolff AC, Zorzi J, Henry NL, Stearns V.

Breast Cancer Res Treat. 2018 May 11. doi: 10.1007/s10549-018-4811-1. [Epub ahead of print]

PMID:
29752687
12.

Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer.

Bardia A, Gucalp A, DaCosta N, Gabrail N, Danso M, Ali H, Blackwell KL, Carey LA, Eisner JR, Baskin-Bey ES, Traina TA.

Breast Cancer Res Treat. 2018 May 9. doi: 10.1007/s10549-018-4813-z. [Epub ahead of print]

PMID:
29744674
13.

Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer.

Spring L, Bardia A.

Clin Cancer Res. 2018 Jul 1;24(13):2981-2983. doi: 10.1158/1078-0432.CCR-18-0463. Epub 2018 Apr 23.

PMID:
29685881
14.

Role of drug transporters and heat shock proteins during ethanol exposure to human neural precursor cells and its lineages.

Vishwakarma SK, Fatima N, Lakkireddy C, Raju N, Bardia A, Sandhya A, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2018 Apr;51:14-23. doi: 10.1016/j.tice.2018.02.001. Epub 2018 Feb 7.

PMID:
29622083
15.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

PMID:
29453314
16.

Bioengineered humanized livers as better three-dimensional drug testing model system.

Vishwakarma SK, Bardia A, Lakkireddy C, Nagarapu R, Habeeb MA, Khan AA.

World J Hepatol. 2018 Jan 27;10(1):22-33. doi: 10.4254/wjh.v10.i1.22.

17.

Targeted therapy for metastatic triple negative breast cancer: The next frontier in precision oncology.

Vidula N, Bardia A.

Oncotarget. 2017 Nov 21;8(63):106167-106168. doi: 10.18632/oncotarget.22580. eCollection 2017 Dec 5. No abstract available.

18.

Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation (VA ECMO) in Adult Patients - Many Questions, Few Answers, and Hard Choices.

Bardia A, Schonberger RB.

J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1183-1184. doi: 10.1053/j.jvca.2017.10.037. Epub 2017 Oct 31. No abstract available.

PMID:
29276089
19.

Expressed Gene Fusions as Frequent Drivers of Poor Outcomes in Hormone Receptor-Positive Breast Cancer.

Matissek KJ, Onozato ML, Sun S, Zheng Z, Schultz A, Lee J, Patel K, Jerevall PL, Saladi SV, Macleay A, Tavallai M, Badovinac-Crnjevic T, Barrios C, Beşe N, Chan A, Chavarri-Guerra Y, Debiasi M, Demirdögen E, Egeli Ü, Gökgöz S, Gomez H, Liedke P, Tasdelen I, Tolunay S, Werutsky G, St Louis J, Horick N, Finkelstein DM, Le LP, Bardia A, Goss PE, Sgroi DC, Iafrate AJ, Ellisen LW.

Cancer Discov. 2018 Mar;8(3):336-353. doi: 10.1158/2159-8290.CD-17-0535. Epub 2017 Dec 14.

PMID:
29242214
20.

Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer.

Condorelli R, Spring L, O'Shaughnessy J, Lacroix L, Bailleux C, Scott V, Dubois J, Nagy RJ, Lanman RB, Iafrate AJ, Andre F, Bardia A.

Ann Oncol. 2018 Mar 1;29(3):640-645. doi: 10.1093/annonc/mdx784.

PMID:
29236940
21.

Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Nagayama A, Ellisen LW, Chabner B, Bardia A.

Target Oncol. 2017 Dec;12(6):719-739. doi: 10.1007/s11523-017-0535-0. Review.

PMID:
29116596
22.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
23.

Enhanced neuroprotective effect of mild-hypothermia with VPA against ethanol-mediated neuronal injury.

Vishwakarma SK, Bardia A, Chandrakala L, Arshiya S, Paspala SAB, Satti V, Khan AA.

Tissue Cell. 2017 Dec;49(6):638-647. doi: 10.1016/j.tice.2017.09.004. Epub 2017 Sep 14.

PMID:
28947065
24.

Mechanism of Action and Clinical Impact of Ribociclib-Response.

Tripathy D, Bardia A, Sellers WR.

Clin Cancer Res. 2017 Sep 15;23(18):5658. doi: 10.1158/1078-0432.CCR-17-1819. No abstract available.

25.

Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer.

Zangardi ML, Spring LM, Blouin GC, Bardia A.

Expert Rev Clin Pharmacol. 2017 Nov;10(11):1169-1176. doi: 10.1080/17512433.2017.1376653. Epub 2017 Sep 18. Review.

PMID:
28875723
26.

Use of Biocompatible Sorafenib-gold Nanoconjugates for Reversal of Drug Resistance in Human Hepatoblatoma Cells.

Vishwakarma SK, Sharmila P, Bardia A, Chandrakala L, Raju N, Sravani G, Sastry BVS, Habeeb MA, Khan AA, Dhayal M.

Sci Rep. 2017 Aug 17;7(1):8539. doi: 10.1038/s41598-017-08878-y.

27.

AKT1low quiescent cancer cells persist after neoadjuvant chemotherapy in triple negative breast cancer.

Kabraji S, Solé X, Huang Y, Bango C, Bowden M, Bardia A, Sgroi D, Loda M, Ramaswamy S.

Breast Cancer Res. 2017 Aug 1;19(1):88. doi: 10.1186/s13058-017-0877-7.

28.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A.

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Review.

29.

Antibody-drug conjugates in breast cancer.

Bardia A.

Clin Adv Hematol Oncol. 2017 Apr;15(4):251-254. No abstract available.

PMID:
28591100
30.

Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics.

Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, Maliakal P, Govindan SV, Sharkey RM, Goldenberg DM.

Cancer. 2017 Oct 1;123(19):3843-3854. doi: 10.1002/cncr.30789. Epub 2017 May 30.

PMID:
28558150
31.

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR.

J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26.

PMID:
28548889
32.

Ultrasound as a Screening Tool for Central Venous Catheter Positioning and Exclusion of Pneumothorax.

Amir R, Knio ZO, Mahmood F, Oren-Grinberg A, Leibowitz A, Bose R, Shaefi S, Mitchell JD, Ahmed M, Bardia A, Talmor D, Matyal R.

Crit Care Med. 2017 Jul;45(7):1192-1198. doi: 10.1097/CCM.0000000000002451.

PMID:
28422778
33.

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.

Tripathy D, Bardia A, Sellers WR.

Clin Cancer Res. 2017 Jul 1;23(13):3251-3262. doi: 10.1158/1078-0432.CCR-16-3157. Epub 2017 Mar 28. Review.

34.

SWISH-ing steroids: new standard of care to prevent everolimus-induced oral mucositis?

Spring L, Bardia A.

Lancet Oncol. 2017 May;18(5):564-565. doi: 10.1016/S1470-2045(17)30106-7. Epub 2017 Mar 15. No abstract available.

PMID:
28314690
35.

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT.

J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14.

36.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

37.

A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.

Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA.

Clin Cancer Res. 2017 Aug 1;23(15):4035-4045. doi: 10.1158/1078-0432.CCR-16-3055. Epub 2017 Mar 7.

38.

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials.

Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, Manning HC, Mahmood U, Ulaner GA.

Clin Cancer Res. 2017 Jun 15;23(12):3053-3060. doi: 10.1158/1078-0432.CCR-16-2197. Epub 2016 Dec 23.

39.

The Association Between Preoperative Hemoglobin A1C and Postoperative Glycemic Variability on 30-Day Major Adverse Outcomes Following Isolated Cardiac Valvular Surgery.

Bardia A, Khabbaz K, Mueller A, Mathur P, Novack V, Talmor D, Subramaniam B.

Anesth Analg. 2017 Jan;124(1):16-22.

PMID:
27861432
40.

Using machine learning to parse breast pathology reports.

Yala A, Barzilay R, Salama L, Griffin M, Sollender G, Bardia A, Lehman C, Buckley JM, Coopey SB, Polubriaginof F, Garber JE, Smith BL, Gadd MA, Specht MC, Gudewicz TM, Guidi AJ, Taghian A, Hughes KS.

Breast Cancer Res Treat. 2017 Jan;161(2):203-211. doi: 10.1007/s10549-016-4035-1. Epub 2016 Nov 8.

PMID:
27826755
41.

Combined Epidural-General Anesthesia vs General Anesthesia Alone for Elective Abdominal Aortic Aneurysm Repair.

Bardia A, Sood A, Mahmood F, Orhurhu V, Mueller A, Montealegre-Gallegos M, Shnider MR, Ultee KH, Schermerhorn ML, Matyal R.

JAMA Surg. 2016 Dec 1;151(12):1116-1123. doi: 10.1001/jamasurg.2016.2733.

PMID:
27603002
42.

HER2 expression identifies dynamic functional states within circulating breast cancer cells.

Jordan NV, Bardia A, Wittner BS, Benes C, Ligorio M, Zheng Y, Yu M, Sundaresan TK, Licausi JA, Desai R, O'Keefe RM, Ebright RY, Boukhali M, Sil S, Onozato ML, Iafrate AJ, Kapur R, Sgroi D, Ting DT, Toner M, Ramaswamy S, Haas W, Maheswaran S, Haber DA.

Nature. 2016 Sep 1;537(7618):102-106. doi: 10.1038/nature19328. Epub 2016 Aug 24.

43.

Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.

Bardia A, Iafrate JA, Sundaresan T, Younger J, Nardi V.

Oncologist. 2016 Sep;21(9):1035-40. doi: 10.1634/theoncologist.2016-0240. Epub 2016 Aug 22.

44.

The Coanda Effect.

Bardia A, Saraf R, Maslow A, Khabbaz K, Mahmood F.

Anesth Analg. 2016 Sep;123(3):582-4. doi: 10.1213/ANE.0000000000001474. No abstract available.

PMID:
27537752
45.

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A.

JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. Review.

46.

Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study.

Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA.

Breast. 2016 Aug;28:191-8. doi: 10.1016/j.breast.2016.06.008. Epub 2016 Jun 20.

47.

Genetic Polymorphisms of X-ray Repair Cross-Complementing Group 1 and Apurinic/Apyrimidinic Endonuclease-1 in Chronic Obstructive Pulmonary Disease.

Bardia A, Vishwakarma SK, Reddy CL, Raju N, Iqbal S, Sravani G, Lavanya N, Begum N, Usma N, Nallari P, Baderuzzaman, Ahmed SM, Hasan A, Khan AA.

Inflammation. 2016 Jun;39(3):1198-204. doi: 10.1007/s10753-016-0355-x.

PMID:
27107596
49.

Early Cellular Changes in the Ascending Aorta and Myocardium in a Swine Model of Metabolic Syndrome.

Saraf R, Huang T, Mahmood F, Owais K, Bardia A, Khabbaz KR, Liu D, Senthilnathan V, Lassaletta AD, Sellke F, Matyal R.

PLoS One. 2016 Jan 14;11(1):e0146481. doi: 10.1371/journal.pone.0146481. eCollection 2016.

50.

Abdominal Cocoon: An enigma.

Habeeb MA, Vishwakarma SK, Abdul Wajid M, Bardia A, Khan AA, Bheerappa N.

Trop Gastroenterol. 2015 Apr-Jun;36(2):130-1. No abstract available.

PMID:
26710487

Supplemental Content

Loading ...
Support Center